诚达药业(301201) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥76,307,845, a decrease of 24.37% compared to ¥100,889,692.80 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥1,399,981.98, representing a decline of 107.51% from a profit of ¥18,644,506 in the previous year[5] - Basic and diluted earnings per share were both -¥0.0092, down 107.57% from ¥0.1215 in the previous year[5] - Net profit for the current period is a loss of ¥1,332,581.61, compared to a profit of ¥18,726,286.19 in the previous period[21] Cash Flow - The net cash flow from operating activities was negative at ¥22,961,570.56, a decrease of 160.29% compared to ¥38,083,815.26 in the same period last year[5] - Cash received from sales and services decreased by 52.45% to ¥63,888,356.57 compared to the previous period[13] - Cash received from other operating activities decreased by 65.27% to ¥2,865,624.18, mainly due to reduced export tax rebates and government subsidies[13] - Cash inflow from operating activities totaled 66,754,011.42, down from 142,615,023.64 in the prior period[26] - Cash outflow from operating activities was 89,715,581.98, compared to 104,531,208.38 previously[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,389,449,308.22, a decrease of 1.93% from ¥2,436,460,004.08 at the end of the previous year[5] - Total liabilities decreased to ¥245,088,305.93 from ¥290,766,420.18, reflecting a reduction of 15.7%[20] - The company's total equity is reported at ¥2,144,361,002.29, down from ¥2,145,693,583.90 in the previous period[20] - The company has a total non-current asset of ¥980,292,139.87, down from ¥1,021,296,347.94 in the previous period[20] Operating Costs and Expenses - Total operating costs decreased to ¥80,611,623.48, down 9.4% from ¥88,945,893.49 in the previous period[21] - The company's management expenses increased by 62.43% to ¥30,808,110.88, primarily due to increased depreciation during the trial production period after project delivery[9] - Research and development expenses for the current period are ¥9,022,289.07, slightly down from ¥9,782,578.34 in the previous period[21] Cash and Investments - The company's cash and cash equivalents increased to ¥445,496,148.82 from ¥178,463,170.90[18] - The company's trading financial assets decreased to ¥645,132,195.37 from ¥957,652,020.32[18] - Cash paid for investments increased significantly by 1390.31% to ¥1,500,000,000.00, mainly due to increased purchases of financial products[13] - The company received cash from investment recovery totaling 1,838,022,696.25 during the current period[27] Government Support - The company received government subsidies amounting to ¥673,984.65 during the reporting period, which were closely related to its normal business operations[6]